Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 May;68(5):723-33.
doi: 10.1007/s00228-011-1200-7. Epub 2011 Dec 30.

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Richard A Larson  1 , Ophelia Q P Yin, Andreas Hochhaus, Giuseppe Saglio, Richard E Clark, Hirohisa Nakamae, Neil J Gallagher, Eren Demirhan, Timothy P Hughes, Hagop M Kantarjian, Philipp D le Coutre
Affiliations
Randomized Controlled Trial

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Richard A Larson et al. Eur J Clin Pharmacol. 2012 May.

Abstract

Purpose: We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase.

Methods: Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacokinetic profiles) were obtained from 542 patients over 12 months. A population pharmacokinetic analysis was performed using nonlinear mixed-effect modeling. Exposure-response relationships were explored graphically or using logistic regression models.

Results: Nilotinib concentrations were stable over 12 months. Patients in the 400 mg twice-daily arm had an 11.5% higher exposure than did those in the 300 mg twice-daily arm, and the relative bioavailability of nilotinib 400 mg twice daily was 0.84 times that of 300 mg twice daily. Patient demographics did not significantly affect nilotinib pharmacokinetics. The occurrence of all-grade total bilirubin elevation was significantly higher in patients with higher nilotinib exposure, and a positive correlation was also observed between nilotinib exposure and QTcF change on electrocardiograms from baseline. There was no significant relationship between nilotinib exposure and major molecular response at 12 months.

Conclusions: There is a less than proportional dose-exposure relationship between nilotinib 300 mg and 400 mg twice-daily doses. Blood level testing is unlikely to play an important role in the general management of patients with newly diagnosed CML treated with nilotinib.

Trial registration: ClinicalTrials.gov NCT00471497.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr Larson received research support, honoraria, and consulting fees from Novartis; Dr Yin is an employee and stock holder of Novartis; Dr Hochhaus has received research support, honoraria, and consulting fees from Novartis and Bristol-Myers Squibb; Dr Saglio has received honoraria and consulting fees from Novartis and Bristol-Myers Squibb; Dr Clark has received research support, honoraria, and consulting fees from Novartis; Dr Nakamae has received honoraria from Novartis and Bristol-Myers Squibb; Dr Gallagher is a Novartis employee and stock holder; Dr. Eren Demirhan is a Novartis employee; Dr Hughes has received research support, honoraria, and consulting fees from Novartis and Bristol-Myers Squibb; Dr Kantarjian has received research support and consulting fees from Novartis; and Dr le Coutre has received research support and honoraria from Novartis and consulting fees from Novartis and Bristol-Myers Squibb.

Figures

Fig. 1
Fig. 1. Mean serum concentration-time profiles of nilotinib obtained at steady state in the full PK cohort
Fig. 2
Fig. 2. Nilotinib Cmin (a) and Cmax (b) over time in the 300 mg twice-daily and 400 mg twice-daily arms
Fig. 3
Fig. 3
Goodness-of-fit plots for the population PK model: observed concentrations versus population (a) and individual (b) predictions. Values <1 (including observed values reported below LLOQ) are plotted at 1.0. The line of identity is plotted as a reference
Fig. 4
Fig. 4. All grade and grade 3/4 reductions in hemoglobin, absolute neutrophils, and platelets (a) and in blood chemistry elevations (b) according to nilotinib Cmin
Fig. 5
Fig. 5. QTcF change from baseline according to nilotinib Cmax at days 8 (a) and 84 (b) and according to nilotinib Cmin at days 8 (c) and 84 (d)
See this image and copyright information in PMC

Comment in

References

    1. Tasigna [package insert] East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.
    1. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765–1769. - PMC - PubMed
    1. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445–453. - PubMed
    1. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129–141. - PubMed
    1. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009;114(24):4933–4938. - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources